Qiu MZ - Search Results

1

Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma.

Zhang Y, Qiu MZ, Wang JF, Zhang YQ, Shen A, Yuan XL, Zhang T, Wei XL, Zhao HY, Wang DS, Zhao Q, Xiong GZ, Ji YP, Liang XJ, Xia G, Xu RH. Zhang Y, et al. Among authors: qiu mz. Cell Rep Med. 2022 Nov 15;3(11):100814. doi: 10.1016/j.xcrm.2022.100814. Cell Rep Med. 2022. PMID: 36384091 Free PMC article. Clinical Trial.

2

[Responses of 109 adult soft tissue sarcoma patients to chemotherapy].

Qiu MZ, Xu F, Wang SS, Luo HY, Wang F, Li FH, Sun XF, Xu GC, Lin TY, Huang HQ, Jiang WQ, Guan ZZ, Xu RH. Qiu MZ, et al. Ai Zheng. 2007 Dec;26(12):1344-9. Ai Zheng. 2007. PMID: 18076798 Free article. Chinese.

3

A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.

Luo HY, Xu RH, Zhang L, Li YH, Shi YX, Lin TY, Han B, Wang F, Qiu MZ, He YJ, Guan ZZ. Luo HY, et al. Among authors: qiu mz. Chemotherapy. 2008;54(3):228-35. doi: 10.1159/000140467. Epub 2008 Jun 18. Chemotherapy. 2008. PMID: 18560231 Clinical Trial.

4

[Progression in palliative chemotherapy for advanced colorectal cancer].

Xu RH, Qiu MZ. Xu RH, et al. Among authors: qiu mz. Ai Zheng. 2008 Jun;27(6):661-6. Ai Zheng. 2008. PMID: 18570745 Free article. Review. Chinese.

5

[Prognosis of 84 intrahepatic cholangiocarcinoma patients].

Li FH, Chen XQ, Luo HY, Li YH, Wang F, Qiu MZ, Teng KY, Li ZH, Xu RH. Li FH, et al. Among authors: qiu mz. Ai Zheng. 2009 May;28(5):528-32. Ai Zheng. 2009. PMID: 19624884 Free article. Chinese.

6

[Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection].

Qiu MZ, Teng KY, Ruan DY, Li YH, Chen XQ, Pan ZZ, He YJ, Wan DS, Xu RH. Qiu MZ, et al. Ai Zheng. 2009 Jul;28(7):743-8. doi: 10.5732/cjc.008.10815. Ai Zheng. 2009. PMID: 19624903 Free article. Chinese.

7

Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma.

Qiu MZ, Lin JZ, Wang ZQ, Wang FH, Pan ZZ, Luo HY, Li YH, Zhou ZW, He YJ, Xu RH. Qiu MZ, et al. Int J Biol Markers. 2009 Oct-Dec;24(4):258-64. doi: 10.1177/172460080902400407. Int J Biol Markers. 2009. PMID: 20082274 Free article.

8

Impact of pretreatment hematologic profile on survival of colorectal cancer patients.

Qiu MZ, Yuan ZY, Luo HY, Ruan DY, Wang ZQ, Wang FH, Li YH, Xu RH. Qiu MZ, et al. Tumour Biol. 2010 Aug;31(4):255-60. doi: 10.1007/s13277-010-0024-x. Epub 2010 Mar 25. Tumour Biol. 2010. PMID: 20336401

9

Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer.

Luo HY, Xu RH, Wang F, Qiu MZ, Li YH, Li FH, Zhou ZW, Chen XQ. Luo HY, et al. Among authors: qiu mz. Chemotherapy. 2010;56(2):94-100. doi: 10.1159/000305256. Epub 2010 Mar 30. Chemotherapy. 2010. PMID: 20357440 Clinical Trial.

10

Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines.

Luo HY, Wei W, Shi YX, Chen XQ, Li YH, Wang F, Qiu MZ, Li FH, Yan SL, Zeng MS, Huang P, Xu RH. Luo HY, et al. Among authors: qiu mz. Oncol Rep. 2010 Jun;23(6):1735-45. doi: 10.3892/or_00000819. Oncol Rep. 2010. PMID: 20428833

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

167 results

Search Page